Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06344819 · ClinicalTrials.gov registry record · Phase 2
An Acupuncture Study for People At High Risk for Sepsis
A Phase 2 study of Sepsis, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT06344819: Recruiting Phase 2 study of Sepsis, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06344819 is a Phase 2 study of Sepsis that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 78 participants, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06344819, a Phase 2 study of Sepsis, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham acupuncture is performed the same way as real acupuncture but will use different needles and target different sites or places on the body than real acupuncture.
Primary Outcome
To assess the feasibility of conducting a randomized controlled trial of acupuncture in hospitalized patients who are at risk for sepsis.
Conditions Studied
Interventions
- PROCEDURE Acupuncture
- OTHER Sham Acupuncture
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-03-20 |
| Est. Completion | 2028-03-20 |
| Phase | Phase 2 |
What NCT06344819 shows while recruiting
NCT06344819 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 6,564-participant average among 90 other Sepsis trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Acupuncture is the first listed.
NCT06344819 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06344819 about?
NCT06344819 is a clinical study titled "An Acupuncture Study for People At High Risk for Sepsis". Researchers think acupuncture may improve outcomes for participants with sepsis, based on laboratory studies and previous studies in people with sepsis. The purpose of this study to see whether real acupuncture can improve outcomes for participants with sepsis when compared to sham acupuncture. Sham...
What is the current status of trial NCT06344819?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2024-03-20. Estimated completion is 2028-03-20.
What conditions does trial NCT06344819 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT06344819?
The interventions under investigation include: Acupuncture (PROCEDURE), Sham Acupuncture (OTHER).
Who is sponsoring clinical trial NCT06344819?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06344819 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06344819's enrollment target sits among peer trials
78 61st of 90 higher than 30 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI